[Frontiers in Bioscience, Landmark, 25, 564-576, Jan 1, 2020]

Silencing NEAT1 suppresses thyroid carcinoma via miR-126/NEAT1/VEGFA axis

Weiwei Zeng1, Yan Lin1, Hai Lin, Xuemei Wu1

1Department of Endocrinology, Rui’an People’s Hospital and The Third Affiliated Hospital of Wenzhou Medical University, rui’an, Zhejiang, 325200, P. R. China


1. Abstract
2. Introduction
3. Material and methods
    3.1. Reagents
    3.2. Cell culture
    3.3. Cell transfection
    3.4. qPCR
    3.5. Luciferase reporter assay
    3.6. BrdU labeling and staining
    3.7. Transwell culture
    3.8. Scratch test
    3.9. Flow cytometry
    3.10. Western blotting
    3.11. RNA Binding-Protein Immunoprecipitation (RIP) assay
    3.12. Pull down assay
    3.13. Establishment of xenograft mouse model
    3.14. Immunohistochemistry
    3.15. Statistic analysis
4. Results
    4.1. NEAT1 is highly expressed in thyroid cancer cells and knockdown of NEAT1 inhibits cell growth and promotes cell apoptosis
    4.2. Knockdown of NEAT1 inhibits migration and epithelial-mesenchymal transition (EMT)
    4.3. miR-126 targets and negatively regulates NEAT1
    4.4. miR-126 regulates VEGFA expression, cell growth and motility and apoptosis
    4.5. Silencing NEAT1 down-regulates VEGFA level, increases apoptosis and inhibits tumor cell growth in vivo
5. Discussion
6. Acknowledgments
7. References


The incidence of papillary thyroid carcinoma (PTC) has steadily increased over the recent years, making this cancer a common malignant tumor world-wide. We tested the hypothesis that Nuclear Enriched Abundant sh-NEAT1 knock-down ranscript 1 (NEAT1) is involved in the pathogenesis of PTC in vitro and in vivo. We show that NEAT1 is highly expressed in Papillary Thyroid Carcinoma cell line (PTC-1) and anaplastic thyroid cancer cell line (SW1736) as compared with the human thyroid follicular epithelial cell line (Nthy-ori 3-1). shRNA knockdown of NEAT1 led to the inhibition of cell growth, invasion, migration and Epithelial to Mesenchymal Transition (EMT) of thyroid cancer cells. This treatment increased the rate of apoptosis in SW1736 cells. Silencing of NEAT1 increased the level of its regulator, miRNA-126 and down-regulated VEGFA that sets the density of tumor vasculature. Administrtation of sh-NEAT1 also inhibited tumor growth in vivo, increased the miRNA-126 level and down-regulated VEGFA. Taken together, these results indicate that silencing NEAT1 suppresses thyroid carcinoma via miR-126/NEAT1/VEGFA axis.


1. R. L. Brown, J. A. de Souza, E. E. Cohen. Thyroid cancer: burden of illness and management of disease. J Cancer. 2, 193-199 (2011)
DOI: 10.7150/jca.2.193

2. M. Nikiforova, Y. Nikiforov. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn., 8, 83-95 (2008)
DOI: 10.1586/14737159.8.1.83

3. H. H. L. Ms, FRACS, K. Y. Wan, FRCR, M. S. Chung-Yau Lo, FRCS. Significance of Metastatic Lymph Node Ratio on Stimulated Thyroglobulin Levels in Papillary Thyroid Carcinoma after Prophylactic Unilateral Central Neck Dissection. Ann Surg Oncol., 19, 1257-1263 (2012)
DOI: 10.1245/s10434-011-2105-5

4. L. Yang, L. Xu, Q. Wang, M. Wang, G. An. Dysregulation of long non-coding RNA profiles in human colorectal cancer and its association with overall survival. Oncol Lett., 12, 4068 (2016)
DOI: 10.3892/ol.2016.5138

5. M. A. Smolle, T. Bauernhofer, K. Pummer, G. A. Calin, M. Pichler. Current Insights into Long Non-Coding RNAs (LncRNAs) in Prostate Cancer. Int J Mol Sci., 18, 473 (2017)
DOI: 10.3390/ijms18020473

6. S. Ghaforui-Fard, M. Taheri. Nuclear Enriched Abundant Transcript 1 (NEAT1): A long non-coding RNA with diverse functions in tumorigenesis. Biomed Pharmacother., 111, 51-59 (2018)
DOI: 10.1016/j.biopha.2018.12.070

7. F. Wu, Q. Mo, X. Wan, J. Dan, H. Hu. NEAT1/has-mir-98-5p/MAPK6 axis is involved in non-small-cell lung cancer (NSCLC) development. J Cell Biochem. 120:2836-2846 (2017)

8. W. Sun, X. Lan, H. Zhang, Z. Wang, W. Dong, L. He, T. Zhang, P. Zhang, J. Liu, Y. Qin. NEAT1_2 functions as a competing endogenous RNA to regulate ATAD2 expression by sponging microRNA-106b-5p in papillary thyroid cancer. Cell Death Dis., 9, 380 (2018)
DOI: 10.1038/s41419-018-0418-z

9. H. Zhang, Y. Cai, L. Zheng, Z. Zhang, X. Lin, N. Jiang. Long noncoding RNA NEAT1 regulate papillary thyroid cancer progression by modulating miR-129-5p /KLK7 expression. J Cell Physiol., 233(10):6638-6648 (2018)
DOI: 10.1002/jcp.26425

10. C. Zhao, Y. Li, M. Zhang, Y. Yang, L. Chang. miR-126 inhibits cell proliferation and induces cell apoptosis of hepatocellular carcinoma cells partially by targeting Sox2. Human Cell, 28, 91-99 (2015)
DOI: 10.1007/s13577-014-0105-z

11. L. Jiang, C. Tao, A. He, X. He. Overexpression of miR-126 sensitizes osteosarcoma cells to apoptosis induced by epigallocatechin-3-gallate. World J Surg Oncol., 12, 383 (2014)
DOI: 10.1186/1477-7819-12-383

12. K. M. Kyeong, J. S. Bong, K. Jong-Sik, R. Mee Sook, L. J. Hyun, L. Eun Hee, L. Hyoun Wook. Expression of microRNA miR-126 and miR-200c is associated with prognosis in patients with non-small cell lung cancer. Virchows Arch., 465, 463-471 (2014)
DOI: 10.1007/s00428-014-1640-4

13. C. Hongxia, L. Lingmin, W. Shaojun, L. Yupeng, G. Qi, L. Nonghua, Z. Xiaodong, C. Changyan. Reduced miR-126 expression facilitates angiogenesis of gastric cancer through its regulation on VEGF-A. Oncotarget, 5, 11873-11885 (2014)
DOI: 10.18632/oncotarget.2662

14. W. Xiaohong, T. Shuang, L. Shu-Yun, L. Robert, J. S. Rader, M. Craig, Z. Zhi-Ming. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One, 3, e2557 (2008)
DOI: 10.1371/journal.pone.0002557

15. Y. Tatsuro, I. Takeru, W. Rika, T. Keiichi, M. Hiroshi, N. Daisuke, N. Yujiro, M. Takeo, H. Shinichiro, M. Michiko. Underexpression of miR-126 and miR-20b in hereditary and nonhereditary colorectal tumors. Oncology, 87, 58-66 (2014)
DOI: 10.1159/000363303

16. Li, Zeng, Li, Nan, Li, Xiayu, Wang, Xiaoyan, Wu, Minghua. Expression of miR-126 suppresses migration and invasion of colon cancer;cells by targeting CXCR4. Mol Cell Biochem., 381, 233-242 (2013)
DOI: 10.1007/s11010-013-1707-6

17. A. Salajegheh, H. Vosgha, M. A. Rahman, M. Amin, R. A. Smith, K. Y. Lam. Interactive role of miR-126 on VEGF-A and progression of papillary and undifferentiated thyroid carcinoma. Hum Pathol., 51, 75-85 (2016)
DOI: 10.1016/j.humpath.2015.12.018

18. X. Yin, K. Shweta, M. A. Zeiger, Z. Lisa, K. Electron. miR-126-3p Inhibits Thyroid Cancer Cell Growth and Metastasis, and Is Associated with Aggressive Thyroid Cancer. Plos One, 10, e0130496 (2015)
DOI: 10.1371/journal.pone.0130496

19. W. Qiang, Z. Jie, B. Lin, W. Tongtong, Z. Haishan, M. Qingjie. miR-126 inhibits papillary thyroid carcinoma growth by targeting LRP6. Oncol Rep., 34, 2202-2210 (2015)
DOI: 10.3892/or.2015.4165

20. Y. Song, J. Sun, J. Zhao, Y. Yang, J. Shi, Z. Wu, X. Chen, G. Peng, Z. Miao, Z. Wang. Non-coding RNAs participate in the regulatory network of CLDN4 via ceRNA mediated miRNA evasion. Nat Commun., 8, 289 (2017)
DOI: 10.1038/s41467-017-00304-1

21. W. Chen, R. Zheng, P. D. Baade, S. Zhang, H. Zeng, F. Bray, A. Jemal, X. Q. Yu, J. He. Cancer statistics in China, 2015. Ca Cancer J Clin, 66, 115-132 (2016)
DOI: 10.3322/caac.21338

22. J. J. Sancho, T. W. J. Lennard, I. Paunovic, F. Triponez, A. Sitges-Serra. Prophylactic central neck disection in papillary thyroid cancer: a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg, 399, 155-163 (2014)
DOI: 10.1007/s00423-013-1152-8

23. Z. Zhu, S. Du, K. Yin, S. Ai, M. Yu, Y. Liu, Y. Shen, M. Liu, R. Jiao, X. Chen, W. Guan. Knockdown long noncoding RNA nuclear paraspeckle assembly transcript 1 suppresses colorectal cancer through modulating miR-193a-3p/KRAS. Cancer Med. 8:261-275 (2018)
DOI: 10.1002/cam4.1798

24. H. Tan, L. Zhao. lncRNA nuclear-enriched abundant transcript 1 promotes cell proliferation and invasion by targeting miR-186-5p/HIF-1alpha in osteosarcoma. J Cell Biochem, 120, 6502-6514 (2019)
DOI: 10.1002/jcb.27941

25. R. Garzon, G. A. Calin, C. M. Croce. MicroRNAs in Cancer. Annu Rev Pathol., 60, 167-179 (2009)
DOI: 10.1146/annurev.med.59.053006.104707

26. W. Xu, A. S. Lucas, Z. Wang, Y. Liu. Identifying microRNA targets in different gene regions. BMC Bioinformatics., 15, 1-11 (2014)
DOI: 10.1186/1471-2105-15-S7-S4

27. F. Ebrahimi, E. Al. miR-126 in human cancers: clinical roles and current perspectives. Exp Mol Pathol., 96, 98-107 (2014)
DOI: 10.1016/j.yexmp.2013.12.004

Abbreviation: TC, thyroid carcinoma; PTC, Papillary thyroid carcinoma; ATC, Anaplastic thyroid cancer; NEAT1, Nuclear Enriched Abundant Transcript 1; lncRNAs; long-chain non-coding RNAs; EMT, epithelial-mesenchymal transition

Key Words: Thyroid carcinoma, Nuclear Enriched Abundant Transcript 1, miR-126, tumorigenesis, VEGFA

Send correspondence to: Xuemei Wu, Department of Endocrinology, Rui’an People’s Hospital and The Third Affiliated Hospital of Wenzhou Medical University, Jiyun mountain road, Anyang street, Ruian, Zhejiang, 325200, P. R. China, Tel: 86- 13906646000, Fax: 0577-65866339, E-mail: z53xb5zj@sina.com